Daptomycin Hospira

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
06-04-2022
Productkenmerken Productkenmerken (SPC)
06-04-2022

Werkstoffen:

daptomycin

Beschikbaar vanaf:

Pfizer Europe MA EEIG

ATC-code:

J01XX09

INN (Algemene Internationale Benaming):

daptomycin

Therapeutische categorie:

Antibacterials for systemic use,

Therapeutisch gebied:

Soft Tissue Infections; Skin Diseases, Bacterial

therapeutische indicaties:

Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Product samenvatting:

Revision: 13

Autorisatie-status:

Authorised

Autorisatie datum:

2017-03-22

Bijsluiter

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPTOMYCIN HOSPIRA 350 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION
daptomycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Daptomycin Hospira is and what it is used for
2.
What you need to know before you are given Daptomycin Hospira
3.
How Daptomycin Hospira is given
4.
Possible side effects
5.
How to store Daptomycin Hospira
6.
Contents of the pack and other information
1.
WHAT DAPTOMYCIN HOSPIRA IS AND WHAT IT IS USED FOR
The active substance in Daptomycin Hospira powder for solution for
injection/infusion is daptomycin.
Daptomycin is an antibacterial that can stop the growth of certain
bacteria. Daptomycin Hospira is used in
adults and in children and adolescents (age from 1 to 17 years) to
treat infections of the skin and the
tissues below the skin. It is also used to treat infections in the
blood when associated with skin infection.
Daptomycin Hospira is also used in adults to treat infections in the
tissues that line the inside of the heart
(including heart valves) which are caused by a type of bacteria called
_Staphylococcus aureus._
It is also
used to treat infections in the blood caused by the same type of
bacteria when associated with heart
infection.
Depending on the type of infection(s) that you have, your doctor may
also prescribe other antibacterials
while you are receiving treatment with Daptomycin Hospira.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DAPTOMYCIN HOSPIRA
YOU SHOULD NOT BE GIVEN DAPTOMYCIN HOSPIRA
If 
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Daptomycin Hospira 500 mg powder for solution for injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Each vial contains 350 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 7 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Each vial contains 500 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 10 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Daptomycin is indicated for the treatment of the following infections
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with complicated
skin and soft-tissue infections
(cSSTI).
-
Adult patients with right-sided infective endocarditis (RIE) due to
_Staphylococcus aureus. _
It is
recommended that the decision to use daptomycin should take into
account the antibacterial
susceptibility of the organism and should be based on expert advice
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with
_ Staphylococcus aureus _
bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with
cSSTI, while in paediatric
patients, use in bacteraemia should be associated with cSSTI.
3
Daptomycin is active against Gram positive bacteria only (see section
5.1). In mixed infec
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 06-04-2022
Productkenmerken Productkenmerken Bulgaars 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 18-04-2018
Bijsluiter Bijsluiter Spaans 06-04-2022
Productkenmerken Productkenmerken Spaans 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 18-04-2018
Bijsluiter Bijsluiter Tsjechisch 06-04-2022
Productkenmerken Productkenmerken Tsjechisch 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 18-04-2018
Bijsluiter Bijsluiter Deens 06-04-2022
Productkenmerken Productkenmerken Deens 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 18-04-2018
Bijsluiter Bijsluiter Duits 06-04-2022
Productkenmerken Productkenmerken Duits 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 18-04-2018
Bijsluiter Bijsluiter Estlands 06-04-2022
Productkenmerken Productkenmerken Estlands 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 18-04-2018
Bijsluiter Bijsluiter Grieks 06-04-2022
Productkenmerken Productkenmerken Grieks 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 18-04-2018
Bijsluiter Bijsluiter Frans 06-04-2022
Productkenmerken Productkenmerken Frans 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 18-04-2018
Bijsluiter Bijsluiter Italiaans 06-04-2022
Productkenmerken Productkenmerken Italiaans 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 18-04-2018
Bijsluiter Bijsluiter Letlands 06-04-2022
Productkenmerken Productkenmerken Letlands 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 18-04-2018
Bijsluiter Bijsluiter Litouws 06-04-2022
Productkenmerken Productkenmerken Litouws 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 18-04-2018
Bijsluiter Bijsluiter Hongaars 06-04-2022
Productkenmerken Productkenmerken Hongaars 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 18-04-2018
Bijsluiter Bijsluiter Maltees 06-04-2022
Productkenmerken Productkenmerken Maltees 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 18-04-2018
Bijsluiter Bijsluiter Nederlands 06-04-2022
Productkenmerken Productkenmerken Nederlands 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 18-04-2018
Bijsluiter Bijsluiter Pools 06-04-2022
Productkenmerken Productkenmerken Pools 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 18-04-2018
Bijsluiter Bijsluiter Portugees 06-04-2022
Productkenmerken Productkenmerken Portugees 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 18-04-2018
Bijsluiter Bijsluiter Roemeens 06-04-2022
Productkenmerken Productkenmerken Roemeens 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 18-04-2018
Bijsluiter Bijsluiter Slowaaks 06-04-2022
Productkenmerken Productkenmerken Slowaaks 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 18-04-2018
Bijsluiter Bijsluiter Sloveens 06-04-2022
Productkenmerken Productkenmerken Sloveens 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 18-04-2018
Bijsluiter Bijsluiter Fins 06-04-2022
Productkenmerken Productkenmerken Fins 06-04-2022
Bijsluiter Bijsluiter Zweeds 06-04-2022
Productkenmerken Productkenmerken Zweeds 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 18-04-2018
Bijsluiter Bijsluiter Noors 06-04-2022
Productkenmerken Productkenmerken Noors 06-04-2022
Bijsluiter Bijsluiter IJslands 06-04-2022
Productkenmerken Productkenmerken IJslands 06-04-2022
Bijsluiter Bijsluiter Kroatisch 06-04-2022
Productkenmerken Productkenmerken Kroatisch 06-04-2022
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Kroatisch 18-04-2018

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten